Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Attenuation of the Side Effect Profile Of Regadenoson: A Randomized Double-Blind Placebo-Controlled Study With Aminophylline in Patients Undergoing Myocardial Perfusion Imaging and Have Severe Chronic Kidney Disease (ASSUAGE-CKD Trial)

NCT01336140 is registered in ClinicalTrials.gov with Rush University Medical Center as lead sponsor.

NCT NCT01336140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01336140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Attenuation of the Side Effect Profile Of Regadenoson: A Randomized Double-Blind Placebo-Controlled Study With Aminophylline in Patients Undergoing Myocardial Perfusion Imaging and Have Severe Chronic Kidney Disease (ASSUAGE-CKD Trial)
Lead sponsor
Rush University Medical Center
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2011
Completion date
May 31, 2012
Enrollment
300 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with severe chronic kidney disease being evaluated with nuclear stress testing of the heart using the stress agent regadenoson